ERBB2 and gastric cancer: Currently, combining ICI inhibitors with HER2 inhibitors (such as Trastuzumab or Margetuximab) has been expected to display promising therapeutic efficacy against HER2‐positive breast and GC,63, 64, 65 and thus we inferred that the feasibility of inhibiting both HER2 and immune checkpoints in ERBB2highTMBhigh GC patients also deserved further investigation, whereas for ERBB2highTMBlow GC patients, our data suggested that HER2‐targeted therapy remained to be a more suitable option than immunotherapy.